BMG762791017 - Common Stock
ROIVANT SCIENCES LTD
NASDAQ:ROIV (5/1/2024, 7:20:10 PM)
After market: 11.21 0 (0%)11.21
+0.31 (+2.84%)
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to various other therapies in various stages of clinical development. The firm advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
ROIVANT SCIENCES LTD
11-12 St. James's Square, Suite 1, 3rd Floor
London
P: 442074003347.0
Employees: 904
Website: http://roivant.com/
Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology.
The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira.
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase...
Solar stocks are racking up a strong day in trading, with several of the renewable energy firms up by double-digits in Wednesday trading.
Here you can normally see the latest stock twits on ROIV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: